Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial

被引：0

作者：

Tetsuo Takehara

Naoya Sakamoto

Shuhei Nishiguchi

Fusao Ikeda

Tomohide Tatsumi

Yoshiyuki Ueno

Hiroshi Yatsuhashi

Yasuhiro Takikawa

Tatsuo Kanda

Minoru Sakamoto

Akihiro Tamori

Eiji Mita

Kazuaki Chayama

Gulan Zhang

Shampa De-Oertel

Hadas Dvory-Sobol

Takuma Matsuda

Luisa M. Stamm

Diana M. Brainard

Yasuhito Tanaka

Masayuki Kurosaki

机构：

[1] Osaka University,

[2] Hokkaido University,undefined

[3] Hyogo College of Medicine,undefined

[4] Okayama University,undefined

[5] Yamagata University,undefined

[6] Nagasaki Medical Center,undefined

[7] Iwate Medical University,undefined

[8] Chiba University,undefined

[9] University of Yamanashi,undefined

[10] Osaka City University,undefined

[11] National Hospital Organization Osaka National Hospital,undefined

[12] Hiroshima University,undefined

[13] Gilead Sciences,undefined

[14] Inc,undefined

[15] Gilead Sciences K.K,undefined

[16] Nagoya City University,undefined

[17] Musashino Red Cross Hospital,undefined

来源：

Journal of Gastroenterology | 2019年 / 54卷

关键词：

Sofosbuvir; Velpatasvir; Decompensated cirrhosis; Advanced liver disease; Direct-acting antivirals;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：87 / 95

页数：8

共 30 条

[1]

Charlton M(2015)Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease Gastroenterology 149 649-659

[2]

Everson GT(2016)Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial Lancet Infect Dis 16 685-697

[3]

Flamm SL(2015)Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis N Engl J Med 373 2618-2628

[4]

Manns M(2017)Liver transplantation in Japan [Japanese] Jpn J Transplant 52 134-147

[5]

Samuel D(1989)Superiority of the Child–Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis Scand J Gastroenterol 24 269-276

[6]

Gane EJ(1987)Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics Hepatology 7 660-664

[7]

Curry MP(2017)Survival in patients with Child–Pugh class C cirrhosis: analysis of the liver transplant registry in Japan Hepatol Res 47 1155-1164

[8]

O’Leary JG(2018)Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States Liver Transpl 24 735-743

[9]

Bzowej N(2017)Outcome of all-oral direct-acting antiviral regimens on the rate of development of hepatocellular carcinoma in patients with hepatitis c virus genotype 1-related chronic liver disease Oncology 93 92-98

[10]

Albers I(2018)HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma J Hepatol 68 25-32

← 1 2 3 →